Bortezomib
Showing 26 - 50 of 1,116
Multiple Myeloma, Myeloma Multiple, Myeloma Trial in Poitiers (Drug and medical device)
Not yet recruiting
- Multiple Myeloma
- +2 more
- Drug and medical device
-
Poitiers, FranceCHU Poitiers
Jun 1, 2023
Multiple Myeloma, High-Risk Cancer Trial in Montreal (Bortezomib following nonmyeloablative allogeneic transplant)
Active, not recruiting
- Multiple Myeloma
- High-Risk Cancer
- Bortezomib following nonmyeloablative allogeneic transplant
-
Montreal, Quebec, CanadaHôpital Maisonneuve-Rosemont
Aug 22, 2022
Waldenström's Macroglobulinemia Trial in Ulm (Dexamethasone, Rituximab, Cyclophosphamide, Dexamethasone, Rituximab,
Active, not recruiting
- Waldenström's Macroglobulinemia
- Dexamethasone, Rituximab, Cyclophosphamide
- Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
-
Ulm, GermanyUniversity Hospital Ulm
May 26, 2022
Multiple Myeloma, Auto Stem Cell Transplant Trial in Hackensack (Bortezomib)
Active, not recruiting
- Multiple Myeloma
- Auto Stem Cell Transplant
- Bortezomib
-
Hackensack, New JerseyJohn Theurer Cancer Center @ Hackensack University Medical Cente
Dec 23, 2022
Multiple Myeloma, Myeloma Trial in Poitiers (Isatuximab, Lenalidomide, Bortezomib)
Active, not recruiting
- Multiple Myeloma
- Myeloma
- Isatuximab
- +3 more
-
Poitiers, FranceCHU Poitiers
Sep 5, 2022
Amyloidosis; Systemic Trial in Beijing (Daratumumab, Bortezomib, Dexamethasone)
Active, not recruiting
- Amyloidosis; Systemic
- Daratumumab
- +2 more
-
Beijing, ChinaPeking Union Medical College Hospital
May 9, 2022
Multiple Myeloma Trial in Oslo, Stavanger, Trondheim (Isatuximab, bortezomib, lenalidomide, dexamethason)
Recruiting
- Multiple Myeloma
- Isatuximab, bortezomib, lenalidomide, dexamethason
-
Roskilde, Denmark
- +3 more
Sep 20, 2022
Relapsed or Refractory Multiple Myeloma Trial (Daratumumab, Pomalidomide)
Withdrawn
- Relapsed or Refractory Multiple Myeloma
- (no location specified)
Jan 26, 2023
Antibody-mediated Rejection Trial in Tehran (Bortezomib)
Recruiting
- Antibody-mediated Rejection
- Bortezomib
-
Tehran, Iran, Islamic Republic ofSBMU
Jan 27, 2022
Plasma Cell Myeloma Trial in Rochester (Bortezomib, Daratumumab, Dexamethasone)
Recruiting
- Plasma Cell Myeloma
- Bortezomib
- +3 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 4, 2023
Relapsed or Refractory Multiple Myeloma Trial in Beijing (Mitoxantrone Hydrochloride Liposome injection, Bortezomib for
Recruiting
- Relapsed or Refractory Multiple Myeloma
- Mitoxantrone Hydrochloride Liposome injection
- +2 more
-
Beijing, Beijing, ChinaBeijing Chaoyang Hospital, Capital Medical University
Jan 16, 2022
Solitary Plasmacytoma Trial in Beijing (radiotherapy, Bortezomib Injection, Lenalidomide)
Recruiting
- Solitary Plasmacytoma
- radiotherapy
- +3 more
-
Beijing, ChinaPeking Union Medical College Hospital
Apr 22, 2022
Multiple Myeloma Based on Multi-omics
Enrolling by invitation
- Multiple Myeloma
- Bortezomib
- Bortezomib
-
Beijing, ChinaBeijng Chao Yang Hospital
Apr 21, 2022
Multiple Myeloma Trial in Hackensack (Fludarabine monophosphate, melphalan, Bortezomib)
Completed
- Multiple Myeloma
- Fludarabine monophosphate, melphalan, Bortezomib
-
Hackensack, New JerseyJohn Theurer Cancer Center at Hackensack University Medical Cent
Apr 29, 2022
GVHD Trial in New York (Bortezomib, Cyclophosphamide)
Active, not recruiting
- GVHD
- Bortezomib
- Cyclophosphamide
-
New York, New YorkNew York University School of Medicine
Apr 15, 2022
Multiple Myeloma, Refractory Multiple Myeloma Trial (procedure, drug, radiation)
Withdrawn
- Multiple Myeloma
- Refractory Multiple Myeloma
- nonmyeloablative allogeneic hematopoietic stem cell transplantation
- +7 more
- (no location specified)
Jan 4, 2023
Primary Systemic Amyloidosis, Light Chain Deposition Disease Trial in United States (drug, genetic, other, procedure)
Active, not recruiting
- Primary Systemic Amyloidosis
- Light Chain Deposition Disease
- bortezomib
- +6 more
-
Denver, Colorado
- +6 more
Aug 24, 2022
Graft-versus-host Disease Trial in New York (Cyclophosphamide, Abatacept, Bortezomib)
Recruiting
- Graft-versus-host Disease
- Cyclophosphamide
- +2 more
-
New York, New YorkNYU Langone Health
Mar 24, 2022
Hematological Malignancy Trial in Detroit (Bortezomib)
Recruiting
- Hematological Malignancy
- Bortezomib
-
Detroit, MichiganHenry Ford hospital
Dec 23, 2021
Lymphoma, Mantle Cell, Mantle Cell Lymphoma Trial run by the NCI (Rituximab (R), EPOCH, Bortezomib (B))
Active, not recruiting
- Lymphoma, Mantle Cell
- Mantle Cell Lymphoma
- Rituximab (R)
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Sep 21, 2021
Multiple Myeloma Trial in Chicago, Milwaukee (Bortezomib, Isatuximab, Cyclophosphamide)
Recruiting
- Multiple Myeloma
- Bortezomib
- +3 more
-
Chicago, Illinois
- +1 more
Mar 14, 2022
Relapsed or Refractory Multiple Myeloma Trial in China (SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone))
Recruiting
- Relapsed or Refractory Multiple Myeloma
- SVd (Selinexor+Bortezomib+dexamethasone)
- Vd (Bortezomib+dexamethasone)
-
Hefei, Anhui, China
- +33 more
Aug 14, 2022